SE has achieved rapid commercial success with VYVGART, driving $4.2 billion in 2025 sales and operational profitability. Learn more about ARGX stock here.
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
1d
"I was fighting to survive": Patients still struggle with preauthorization despite promise of reform
Last summer, the Trump administration announced a voluntary pledge by health insurers to reform prior authorization, but patient advocates and medical providers remain skeptical.
A single intravenous ketamine infusion was safe and well-tolerated in older adults with mild cognitive impairment (MCI) and depression (MCI-D), with no serious adverse events (AEs) reported, a small ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...
Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for the would-be blockbuster as a treatment for generalised myasthenia gravis (gMG). It isn ...
Johnson & Johnson's Imaavy has become the first FcRn blocker to be approved in the EU as a treatment for both adolescent and adult patients with generalised myasthenia gravis (gMG), taking on rivals ...
The MG Cyberster is an upcoming two-door electric roadster that has striking looks and a fighter-jet like cockpit. It also offers bonkers performance, courtesy of the dual motors putting out 510 PS ...
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results